PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-27.92%
Both yoy net incomes decline, with AXSM at -8.05%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
3.10%
Less D&A growth vs. AXSM's 8.05%, reducing the hit to reported earnings. David Dodd would confirm that core assets remain sufficient.
No Data
No Data available this quarter, please select a different quarter.
-10.46%
Negative yoy SBC while AXSM is 4.93%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
292.72%
Well above AXSM's 69.45% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
215.28%
AP growth well above AXSM's 158.80%. Michael Burry would be concerned about potential late payments or short-term liquidity strain relative to competitor.
292.72%
Some yoy usage while AXSM is negative at -92.65%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
-67.58%
Negative yoy while AXSM is 100.73%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-21.90%
Both yoy CFO lines are negative, with AXSM at -5.44%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
-11.48%
Both yoy lines negative, with AXSM at -1270.33%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-11.48%
Both yoy lines negative, with AXSM at -1270.33%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
No Data
No Data available this quarter, please select a different quarter.
-59.52%
Both yoy lines negative, with AXSM at -59.99%. Martin Whitman suspects an environment or preference for internal financing over new equity in the niche.
No Data
No Data available this quarter, please select a different quarter.